COMMISSIONING OF HEPATITIS C

Andy Ustianowski
We have huge potential
Many new therapies....

**Structural**
- Capsid shell
- Envelope glycoproteins

**Non-structural**
- Viral assembly
- Protease
- NS4A
- Membranous web formation
- Viral replication or assembly
- RNA-dependent RNA polymerase

**Protease inhibitors**

**NS5A inhibitors**

**NUC inhibitors**
- Non-NUC inhibitors

**Directly Acting Antivirals (DAAs)**

**Capsid shell**

**Envelope glycoproteins**

**Translation and polyprotein processing**
- NS3/4 protease inhibitors

**Receptor binding and endocytosis**

**Virion assembly**
- NS5B polymerase inhibitors
- Nucleos(t)ide Non-nucleoside

**RNA replication or assembly**

**Membranous web formation**

**Transport and release**

**Viral uncoating**

**Structural**
- CORE
- E1
- E2

**Non-structural**
- P7
- NS2
- NS4A
- NS4B
- NSSA
- NS5B


**NUC: nucleos(t)ide**

Feeney ER, Chung RT. BMJ 2014;349:g3308;
And now excellent efficacy...


NOTE: not a cross-study comparison; figure shows data from different heterogeneous studies

DAA: direct-acting antiviral agent
GT: genotype
PI: protease inhibitor
SMV: simeprevir
But there are issues

Specialised Commissioning

CCG

Local Authority / Public Health

Rx

Care

Testing
What happened initially - NHSE
The NICE process was ongoing...
And then…

Sofosbuvir for treating chronic hepatitis C

Technology appraisal guidance
Published: 25 February 2015
nice.org.uk/guidance/ta330

Clinical Commissioning Policy Statement:
Treatment of chronic Hepatitis C in patients with cirrhosis
What else was happening? - NICE
What has now happened?

Run Rates

CQUIN

Liability
How is this going to play out?

Precedent for other areas?